BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Clinical Trial

Official title:

A Multicenter, Open Phase Ⅰ/Ⅱa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BR790 in Combination With Anlotinib in Subjects With Advanced Non-small Cell Lung Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05715398
• Other study ID #: BR790-103
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: February 2023
• Est. completion date: December 2025

Study information

• Verified date: January 2023
• Source: Shanghai Gopherwood Biotech Co., Ltd.
• Contact: Baohui Han, professor
• Phone: 18930858216
• Email: 18930858216[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase Ⅰ/Ⅱa, multi-center, open-label study, aiming to evaluate the safety, tolerability, pharmacokinetic (PK), and efficacy of BR790 in combination with anlotinib in adult participants with advanced NSCLC.

Description:

This study is a Phase Ⅰ/Ⅱa, multi-center, open-label study of BR790 in combination with anlotinib with a dose escalation part followed by a dose expansion part in adult subjects with advanced NSCLC. Participants will be treated until disease progression per RECIST v1.1, unacceptable toxicity, or other criteria for withdrawal are met, whichever occurs first.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 90
• Est. completion date: December 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age =18 and =75 years old.

• Subjects with histologically or cytologically confirmed locally advanced or relapsed metastatic driver negative (EGFR, ALK, ROS, etc.) advanced NSCLC,whose disease progressed after at least 2 previous standard therapies.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

• Has at least one measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) .

Exclusion Criteria:

• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

• Has uncontrolled moderate to massive effusion.

• Central lung squamous carcinoma along with cavum, or non-small cell lung cancer along with hemoptysis (>50ml/day).

• Other kinds of malignancies within 5 years or for now.

• Has not enough organ functional reserve at baseline, which met at least one of the following criteria: ANC<1.5×10^9/L, PLT<100×10^9/L, Hb<100g/L; TBIL>1.5×ULN, ALT or AST>2.5×ULN (without liver metastases) , ALT or AST>5×ULN (with liver metastases);Cr >1.5×ULN, urine protein=++,or confirmed 24h urine protein=1.0g;INR >1.5×ULN, PT>1.5ULN or APTT >1.5×ULN.

• Previous use of other SHP2 inhibitors (such as TNO-155, JAB-3312, JAB-3068, RLY-1971, RMC-4630, etc.)

• Has used anlotinib before

• The first assessment of efficacy was PD, or occurred =grade 3 adverse reactions with antitumor angiogenesis small-molecule drugs (e.g. Apatinib, surufatinib, fruquintinib, etc.), or less than 6 months after the last antitumor vascular therapy.

• Has got non remissive toxic reactions derived from previous therapies, which is over level 1 in CTC AE (5.0), alopecia and grade 2 peripheral neuropathy are not included.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-Small Cell Lung Cancer

Intervention

Drug:
• BR790+anlotinib
BR790 will be administered orally, variable dose on Day 1 of each 21-day cycle, Anlotinib will be administered as PO fixed dose on Day1-14 of each 21-day cycle

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Gopherwood Biotech Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose/Recommended Phase ? Dose(MTD/RP2D)	To evaluate the MTD/RP2D of BR790 in combination with anlotinib (Part 1)	2 years
Primary	Objective Response Rate (ORR)	To evaluate the objective response rate (ORR) of BR790 in combination with anlotinib. ORR is defined as the proportion of subjects who achieve a Complete Response (CR) or Partial Response (PR) as assessed by RECIST v1.1 (Part 2)	2 years
Secondary	Progression-Free Survival (PFS)	PFS was defined as the time from randomization to documented disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) or death due to any cause, whichever occurred first.	2 years
Secondary	Duration of overall response (DOR)	DOR is defined as the time from the first documented CR or PR per RECIST v1.1 to disease recurrence or disease progression (PD) whichever occurs first.	2 years
Secondary	Disease Control Rate(DCR)	DCR is defined as the proportion of subjects who achieve a Complete Response (CR) ?Partial Response (PR) or Stable Disease (SD) as assessed by RECIST v1.1	2 years
Secondary	Overall Survival (OS)	OS is defined as the time from study treatment initiation to death from any cause or last day known to be alive.	2 years
Secondary	Adverse Events(AEs)	Incidence, nature, and severity of treatment-emergent AEs and serious AEs, including incidence and severity of findings in laboratory values and vital signs for combination therapy	2 years
Secondary	Area under the plasma concentration-time curve (AUC)	Area under the plasma concentration time curve of BR790/anlotinib	2 years
Secondary	Plasma concentration (Cmax)	Highest observed plasma concentration of BR790/anlotinib	2 years